Core Viewpoint - Deutsche Bank upgraded Teladoc Health to Buy from Hold with a price target of $11, citing attractive valuation and a credible turnaround strategy for the BetterHelp segment [1] Group 1: Valuation and Market Position - Teladoc shares are currently trading at approximately 4.2 times Deutsche Bank's 2026 EBITDA estimate, one of the lowest multiples in the firm's coverage universe [2] - Such low valuations are typically associated with companies facing existential risks, which Deutsche Bank believes does not apply to Teladoc's expanding Integrated Care segment [2] Group 2: BetterHelp Segment Strategy - The BetterHelp business has been experiencing declines, but management has introduced a strategy to stabilize and grow the segment by shifting from a cash-pay model to insurance-covered therapy services [3] - Demand for insured therapy services is increasing, as evidenced by Universal Health Services' recent acquisition of Talkspace, a competitor in the insured therapy market [4] Group 3: Potential for Value Unlocking - The acquisition of Talkspace suggests a potential upside for Teladoc's current share price, indicating a path for unlocking value in the market [4]

Summary of Teladoc Conference Call Company Overview - **Company**: Teladoc Health - **CEO**: Chuck Divita - **Industry**: Telehealth and Integrated Care Key Points CEO Tenure and Company Performance - Chuck Divita reflects on his two-year tenure, noting both strengths and challenges faced at Teladoc, emphasizing the need for increased strategic focus, operational rigor, and product innovation [4] - The company aims to strengthen its position heading into 2026, particularly focusing on BetterHelp, which constitutes about 40% of revenues [4] CFO Search - The search for a new CFO is ongoing, with a focus on finding a candidate with financial expertise and operational rigor [5] Integrated Care Business Performance - Integrated Care has shown low- to mid-single-digit growth with EBITDA margins in the low double-digit to mid-teens range [6] - The business is transitioning from a subscription-based model to a fee-for-service model, driven by market demand for visit-based arrangements [7][24] - The company has seen good underlying growth in visit revenues, particularly in chronic care, which has experienced enrollment growth [9][8] Membership and Guidance - Teladoc has approximately 100 million members, with a projected low single-digit decline in membership for the year due to external healthcare factors [10][14] - Membership has grown by about 40% since 2020, but challenges such as Medicaid redeterminations and changes in the Affordable Care Act may impact retention [15] Chronic Care Segment - Sequential growth in chronic care enrollment is expected, with opportunities for upselling and engaging new members [17][20] - The company aims to penetrate its existing member base more deeply, particularly in weight management services [21] BetterHelp Business Update - BetterHelp has faced volatility but is expected to stabilize as the company pivots towards insurance coverage, which is anticipated to drive growth [30][31] - The direct-to-consumer cash pay model has seen high drop-off rates, with over 80% of potential users not converting due to cost barriers [34] - The company expects to see increased user engagement and lifetime value as insurance coverage expands [36] Financial Guidance and Debt Management - For fiscal 2026, Teladoc anticipates revenue growth driven by insurance scaling and international growth, with projected insurance revenues of $75 million to $90 million [43] - The company plans to pay down a significant portion of its $1 billion debt due next year, leveraging existing cash and traditional term debt [51][52] Market Position and Competitive Landscape - The company views recent M&A activity in the behavioral health space as validation of the demand for virtual mental health services [39] - Teladoc has a strong market position with over 12,000 clients and a significant data advantage, which is crucial for AI deployment in healthcare [55] AI and Future Outlook - Teladoc is actively investing in AI to enhance engagement and service delivery, leveraging its extensive data to improve clinical interventions [54][56] - The company believes its deep expertise in healthcare and regulatory knowledge creates competitive moats in the telehealth industry [56] Additional Insights - The transition to visit-based revenues is seen as beneficial for service engagement, despite some initial headwinds from the subscription model [25] - The company is focused on operational efficiency and cost management to drive EBITDA results [43]

Core Insights - Teladoc Health, Inc. reported a solid finish for 2025, with consolidated revenue and adjusted EBITDA exceeding guidance for the fourth quarter [3][4] - The company is focused on disciplined execution and performance acceleration, aiming to enhance care delivery and outcomes through product innovation and technology advancements [4] Financial Performance - Fourth Quarter 2025 revenue was $642.3 million, a slight increase from $640.5 million in Fourth Quarter 2024, while Full Year 2025 revenue decreased by 2% to $2,530.0 million from $2,569.6 million in Full Year 2024 [5][10] - Net loss for Fourth Quarter 2025 was $25.1 million, or $0.14 per share, a significant improvement from a net loss of $48.4 million, or $0.28 per share, in Fourth Quarter 2024; Full Year 2025 net loss was $200.3 million, or $1.14 per share, compared to $1,001.2 million, or $5.87 per share, in Full Year 2024 [6][11] - Adjusted EBITDA for Fourth Quarter 2025 was $83.8 million, up 12% year-over-year, while Full Year 2025 adjusted EBITDA decreased by 10% to $281.1 million [7][14] Revenue Breakdown - Access fees revenue in Fourth Quarter 2025 decreased by 4% to $521.6 million, while other revenue increased by 24% to $120.7 million; U.S. revenue decreased by 3% to $517.3 million, and International revenue increased by 19% to $125.0 million [5][10] - For Full Year 2025, access fees revenue decreased by 6% to $2,091.9 million, while other revenue increased by 24% to $438.0 million; U.S. revenue decreased by 4% to $2,071.7 million, and International revenue increased by 12% to $458.2 million [10] Segment Performance - Integrated Care segment revenue increased by 5% to $409.1 million in Fourth Quarter 2025, while BetterHelp segment revenue decreased by 7% to $233.2 million [5][32] - For Full Year 2025, Integrated Care segment revenue increased by 3% to $1,579.6 million, while BetterHelp segment revenue decreased by 9% to $950.4 million [10][32] Cash Flow and Capital Expenditures - Operating cash flow for Full Year 2025 was $294.4 million, flat year-over-year, while free cash flow decreased by 2% to $166.9 million [7][15] - Capital expenditures for Full Year 2025 were $127.5 million, compared to $124.1 million in Full Year 2024 [15] Financial Outlook - For Full Year 2026, the company expects revenue between $2,470 million and $2,587 million, with adjusted EBITDA projected between $266 million and $308 million [18] - The first quarter of 2026 is expected to generate revenue between $598 million and $620 million, with adjusted EBITDA between $50 million and $62 million [19]

Core Viewpoint - Teladoc Health has experienced a significant decline in market value, losing over 98% in the past five years, and is struggling to regain its previous success during the pandemic [1] Industry Overview - Demand for telemedicine services peaked during the pandemic, with usage increasing from 5% pre-pandemic to 42.1% during, and settling at 21.8% post-pandemic, which is still above pre-2019 levels [3] - The telemedicine sector is facing intense competition, particularly from larger corporations like Amazon, which poses challenges for Teladoc's growth, especially in its virtual therapy service, BetterHelp [4] Company Initiatives - Teladoc is attempting to address competition by seeking third-party coverage for BetterHelp to enhance demand and has launched new services such as continuous health monitoring and chronic care [5] - The company is also expanding internationally, with international revenue growing faster than domestic revenue in recent quarters [5] Financial Performance - Despite efforts to grow, Teladoc's revenue is increasing slowly, and the company is currently operating at a loss, with concerns that international expansion may lead to similar challenges as faced domestically [7] - The company has not yet secured broad health insurance coverage for its therapy services, even after acquiring UpLift, which has 100 million covered lives, indicating that third-party coverage does not guarantee demand or revenue [8] Future Outlook - The outlook for Teladoc appears bleak, with significant challenges ahead, and the stock price recently trading at $4.90, raising concerns that it could approach $0 in the next five years [9]

Core Insights - Teladoc Health, Inc. (TDOC) is expected to report a fourth-quarter 2025 loss of 19 cents per share on revenues of $633.91 million, with a year-over-year revenue decrease of 1% [1][2][7] Financial Performance - The fourth-quarter earnings estimate has improved by a penny over the past 60 days, indicating a year-over-year improvement of 32.1% in the bottom line [2] - For the full year 2025, the Zacks Consensus Estimate for Teladoc's revenues is $2.52 billion, reflecting a decline of 1.9% year over year, while the EPS estimate is a loss of $1.20, showing an improvement of 79.6% year over year [3] Earnings Expectations - Teladoc has beaten earnings estimates in three of the last four quarters, with an average surprise of 14.5% [3] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 2 (Buy), which does not conclusively predict an earnings beat this time [4] Segment Performance - Integrated Care members are expected to increase by 9.1%, with segment EBITDA rising by 20.9% year over year [7][10] - BetterHelp revenue is projected to decline by 6.2%, with paying users down by 5% in Q4, and the adjusted EBITDA from this segment is expected to fall by 28.9% year over year [9][10] Revenue Breakdown - The Zacks Consensus Estimate for fourth-quarter Access fees revenues indicates a 1.3% year-over-year decline, while U.S. operations are expected to have declined, partially offset by increased revenues from international operations [8] - Overall adjusted EBITDA is expected to be between $73 million and $90 million, with free cash flow for the full year 2025 projected to be between $170 million and $185 million [10]

Core Insights - Teladoc Health is focusing on execution in 2026 after a year of strategic shifts, including international expansion and improved operational efficiency [1][3] - The company aims for sustainable long-term growth following a significant decline in stock price since the COVID-19 pandemic [2] - Teladoc has made multiple acquisitions, launched new products, and started accepting insurance for its BetterHelp mental health service [2][3] Strategic Focus - The CEO emphasized the importance of execution, stating that the company has the right strategy and priorities in place [3] - A key initiative includes accepting insurance at BetterHelp to enhance value and improve enrollment and retention [4][5] Performance Metrics - Early metrics indicate that the integration of the acquired company UpLift and the rollout of insurance coverage are progressing well, with solid user conversion and session metrics [5][6] - The insurance offering is expected to alleviate affordability concerns for consumers, allowing them to focus more on therapy [6]

Core Insights - Telehealth services offer convenience and potential savings for both physicians and patients, yet companies like Teladoc Health and Doximity have struggled in recent years [1][2] Group 1: Telehealth Market Dynamics - Medicare's reimbursement for telehealth services is set to expire on January 31, limiting coverage to specific cases, which is expected to reduce demand for telehealth [5][8] - The early pandemic years saw increased accessibility to telemedicine, but the upcoming changes in Medicare policy may reverse some of these gains [4] Group 2: Company Performance Outlook - Teladoc is anticipated to experience continued weak performance in 2026, with slow revenue growth and ongoing profitability challenges, exacerbated by the Medicare changes [6][7] - Doximity, while less affected by Medicare changes due to its broader service offerings, still faces a dim outlook in the current market environment [8][10] - Teladoc's international expansion shows some promise, but the company faces significant challenges that may hinder its recovery [9]

Group 1: Sarepta Therapeutics - Sarepta Therapeutics' shares declined by over 80% last year due to safety concerns surrounding its key product, Elevidys, which targets Duchenne muscular dystrophy (DMD) [3][4] - The company had to include a boxed warning for potential liver injury and restrict access to Elevidys after two patients died from liver failure [4][6] - For 2025, Sarepta expects revenue of $1.86 billion, a decline from $1.9 billion in the previous year, indicating a drop in demand for its medicine [6] - Despite efforts to develop new medicines and potential clinical progress, these products are not expected to impact financial performance in the near term [6][7] - Concerns remain regarding the safety of Sarepta's pipeline products, which could further affect investor confidence [7] Group 2: Teladoc Health - Teladoc Health has faced slow to non-existent revenue growth and accumulated net losses in recent years [8] - Increased competition in the telemedicine space has undermined Teladoc's market share, particularly affecting its virtual therapy platform, BetterHelp, which has seen a decline in paying members [9][10] - The company is attempting to improve its situation by seeking broader insurance coverage for BetterHelp and expanding internationally, but challenges similar to those faced domestically are anticipated abroad [12][13] - Teladoc's market cap stands at $1.1 billion, with a current price of $6.16, reflecting ongoing struggles in the market [11][12]

Transforming how better health happens J.P. Morgan Healthcare Conference January 2026 Safe Harbor This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of ...

Core Viewpoint - Teladoc Health has experienced a significant decline in stock value, currently trading about 98% lower than its peak in February 2021, raising questions about whether the shares are undervalued enough to consider a buy [1][2]. Financial Performance - In Q3 2025, Teladoc's revenue decreased by 2% year over year to approximately $626 million, with integrated care revenue rising by 2% to about $390 million, while BetterHelp revenue fell by 8% to around $237 million [4]. - The company reported a net loss of $49.5 million in Q3, which included a $12.6 million non-cash goodwill impairment charge, indicating ongoing struggles despite generating $67.9 million in free cash flow [11][12]. Membership and Growth Metrics - Teladoc's U.S. integrated care membership reached 102.5 million, reflecting a 9% year-over-year increase, while chronic care program enrollment was 1.17 million, showing a slight decline of 1% year over year but a sequential increase of over 4% [5]. - Key metrics for BetterHelp, such as conversion rates and user growth, are reportedly trending as expected, although the direct-to-consumer cash-pay business faces challenges due to competition [7][8]. Future Outlook - The company anticipates Q4 2025 revenue to be between $622 million and $652 million, which is lower than the previous year's Q4 revenue of approximately $640 million [13]. - Management has indicated that 2025 will be a "repositioning year" focused on product changes and improving the value proposition, particularly for BetterHelp [2][6].